John E. Trusheim
Abbott Northwestern Hospital
7 Papers
John E. Trusheim is an academic researcher from Abbott Northwestern Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans-Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven-Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival, and overall adverse events withDCVax were comparable to standard Therapy alone.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Ansstas,Charles Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudhary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Lynne P. Taylor,Julian K. Wu,Erin M. Dunbar,Arnold B. Etame,Santosh Kesari,David Mathieu,David Piccioni,David S. Baskin,Michel Lacroix,Sven-Axel May,Pamela New,Timothy J. Pluard,Steven A. Toms,Victor Tse,Scott Peak,John L. Villano,James Battiste,Paul Mulholland,Michael Pearlman,Kevin Petrecca,Michael Schulder,Robert M. Prins,Alton L. Boynton,Marnix L. Bosch +72 more
TL;DR: In this article , treatment with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) was associated with improved overall survival (OS) for patients with newly diagnosed glioblastoma (nGBM) and recurrent gliomatosis (rGBM), compared with standard of care (SOC).
Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (2018) (142)] DOI: 10.1186/s12967-018-1507-6
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: This Correction corrects an error in the spelling of one of the author names and correct versions of the affected sentence are indicated.
Carboplatin-associated Cranial Neuropathy.
TL;DR: A case of persistent third and fourth nerve palsies after systemic administration of intra-arterial carboplatin for glioblastoma multiforme is described.
12
Ctim-27. autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Anstass,Charles K. Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Marnix L. Bosch +49 more
TL;DR: In this article , the authors evaluated whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to standard of care (SOC) extends survival in glioblastoma patients.
4